SCHEMBL38653301

SCHEMBL38653301

CN(C)c1cc(F)c2c(c1)CN(C(=O)OC(C)(C)C)CC2

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ESR2 Q92731 1/20 0.50
▸ NR1H2 P55055 2/20 0.49
▸ MAPK1 P28482 1/20 0.44
▸ ADORA1 P30542 2/20 0.41
▸ MAPT P10636 3/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ MKNK1 Q9BUB5 4/20 0.40
▸ HPGDS O60760 1/20 0.38
▸ PARP1 P09874 1/20 0.38
▸ TNKS2 Q9H2K2 1/20 0.38
▸ PARP2 Q9UGN5 1/20 0.38
▸ UCHL1 P09936 1/20 0.38
▸ DDB1 Q16531 1/20 0.38
▸ CRBN Q96SW2 1/20 0.38
▸ P2RX3 P56373 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38653272 0.89 ESR2 (0.41) ESR2NR1H2MAPK1MAPTKDM4E
SCHEMBL30199220 0.84 ESR2 (0.63) ESR2NR1H2MAPK1ADORA1MAPT
SCHEMBL38653711 0.83 ESR2 (0.52) ESR2NR1H2MAPK1ADORA1MAPT
SCHEMBL38653323 0.82 ESR2 (0.49) ESR2NR1H2MAPK1ADORA1MAPT
SCHEMBL29586570 0.82 ESR2 (0.51) ESR2NR1H2MAPK1ADORA1MAPT
SCHEMBL21326124 0.82 ESR2 (0.51) ESR2NR1H2MAPK1ADORA1MAPT
SCHEMBL21326079 0.79 NR1H2 (0.69) ESR2NR1H2MAPK1MAPTDDB1
SCHEMBL21326100 0.79 ESR2 (0.70) ESR2NR1H2MAPK1MAPTDDB1
SCHEMBL29587366 0.79 ESR2 (0.70) ESR2NR1H2MAPK1MAPTDDB1
SCHEMBL29586905 0.79 NR1H2 (0.69) ESR2NR1H2MAPK1MAPTDDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026099404-A1 SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER QUBIT PHARMACEUTICALS (FR) 2026-05-15 — — WO disclosed
EP-4741375-A1 SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER Qubit Pharmaceuticals (FR) 2026-05-13 — — EP disclosed
Send feedback